Immune Response to Elasomeran Vaccination

What is the evidence for immune response and protection after Elasomeran vaccination?

Evidence demonstrates that elasomeran vaccination induces robust immune responses and clinical protection across most populations, though patients with hematologic malignancies and those on B-cell-depleting therapies show attenuated responses that improve with additional doses.

Abstract

Elasomeran vaccination demonstrates high efficacy in healthy populations, with risk ratios of 0.08 for preventing COVID-19 and breakthrough infection rates of 0.23%. In immunocompromised populations, humoral responses vary substantially by underlying condition: seropositivity rates reach 95.2% in lung cancer patients, 91.7% in multiple myeloma, and 82% in rheumatic disease patients, but only 60-66% in hematologic malignancies. Cellular immune responses occur in approximately 46% of cancer patients, with most mounting both CD4+ and CD8+ T-cell responses. Antibody titers decline substantially over time, decreasing from median 429 to 139 BAU/mL between 36 days and 3 months post-vaccination, with 10% of initially seropositive patients converting to seronegative status. Response heterogeneity is explained by specific mechanisms: B-cell-depleting therapies (anti-CD20, anti-CD38) profoundly suppress antibody production, disease remission predicts superior response (median titers 1242 vs 221.5 U/ml), and mRNA vaccines induce higher antibody levels than viral vector vaccines. Additional doses substantially improve seroconversion in immunocompromised patients, increasing rates from 26% after two doses to 71.7% after four doses in kidney transplant recipients and from 69.6% to 95.7% after a second dose in AML/MDS patients. Clinical protection remains robust in most immunocompromised populations, with breakthrough infection rates of only 0.5% in lung cancer patients. The evidence indicates that while elasomeran induces strong immune responses in most populations, patients with hematologic malignancies and those receiving B-cell-depleting therapies require additional doses and may need more frequent boosting to maintain protective immunity.

Methods

We analyzed 10 sources from an initial pool of 200, using 7 screening criteria. Each paper was reviewed for 8 key aspects that mattered most to the research question:

• Elasomeran Vaccination: Involvement of Elasomeran (mRNA-1273) vaccination.
• Relevant Outcomes: Measurement of immune response or protection outcomes.
• Human Participants: Inclusion of human participants only.
• Study Design: RCT, cohort, case-control, etc.
• Sample Size: Minimum of 10 participants.
• Full-Text Availability: Full text must be available.
• Biological Outcomes Focus: Focus on biological outcomes rather than safety/reactogenicity or logistical aspects.

Results

Characteristics of Included Studies

Ten studies met the inclusion criteria, comprising two meta-analyses, one scoping review, and seven primary observational studies. Full text was available for six studies, while four studies were only available as abstracts.

Humoral Immune Response

Seropositivity Rates in Healthy vs Immunocompromised Populations

In the healthy population meta-analysis, both BNT162b2 and mRNA-1273 demonstrated high efficacy in preventing COVID-19 compared to placebo (RR 0.08). Breakthrough infection rates were substantially lower with elasomeran (0.23%) compared to placebo (3.29%). Among immunocompromised populations, seropositivity rates varied considerably by underlying condition.

Antibody Durability

In lung cancer patients, antibody levels were maintained post-vaccination. However, in the broader cancer population, median titers declined significantly from 429 BAU/mL at 36 days to 139 BAU/mL at 3 months. Among initially seropositive patients, 10% converted to seronegative status by 3 months.

Response to Multiple Doses

In kidney transplant recipients, seroconversion increased progressively with additional doses. After two initial doses, 26% achieved seroconversion. A third dose improved seroconversion by an additional 31.2%, resulting in final rates of 71.7% for the heterologous scheme and 70.6% for the homologous scheme.

Cellular Immune Response

Data on cellular immunity were limited. Among cancer patients, 46% of solid cancer patients and 45% of hematologic cancer patients exhibited positive T-cell responses.

Clinical Protection Outcomes

Among lung cancer patients, only 0.5% experienced breakthrough infections post-vaccination. Performance status and comorbidities significantly influenced clinical protection.

Factors Modifying Immune Response

Cancer Treatment and Immunosuppression

Certain cancer treatments affected humoral response. In multiple myeloma patients, treatments like lenalidomide maintenance led to higher antibody titers.

Disease-Specific Response Patterns

Seropositivity rates varied widely depending on specific hematologic malignancies, with higher rates in conditions like diffuse large B cell lymphoma compared to mantle cell lymphoma.

Vaccine-Specific Differences

In rheumatic disease patients, those receiving mRNA vaccines showed higher optimal humoral response rates compared to viral vector vaccines.

Safety and Tolerability

Safety data were limited, with mild injection site pain and systemic reactions noted, but no direct links to serious adverse events.

Synthesis

The evidence demonstrates substantial heterogeneity in immune responses to elasomeran vaccination explained by distinct underlying mechanisms. Population-specific response margins and treatment-dependent variations were observed, and disease state served as a significant predictor of immune capacity.